Marker Therapeutics (MRKR) Operating Leases (2019 - 2023)

Marker Therapeutics (MRKR) has reported Operating Leases for 5 consecutive years, with $6.8 million the latest figure, recorded in Q1 2023.

• On a quarterly basis, Operating Leases fell 41.78% year-over-year to $6.8 million in Q1 2023; TTM through Mar 2023 was $6.8 million, a 41.78% decrease from a year earlier, with the FY2022 full-year figure at $7.0 million, down 37.42% from the prior year.
• Operating Leases was $6.8 million for Q1 2023 at Marker Therapeutics, down from $7.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $12.2 million in Q3 2020 and troughed at $280247.0 in Q4 2019.
• A 5-year average of $7.5 million and a median of $9.5 million in 2020 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases surged 4134.99% in 2020 and plunged 41.78% in 2023, its largest moves.
• Over 5 years, Operating Leases stood at $280247.0 in 2019, then surged by 4134.99% to $11.9 million in 2020, then dropped by 5.23% to $11.2 million in 2021, then sank by 37.42% to $7.0 million in 2022, then retreated by 3.06% to $6.8 million in 2023.
• The last three Operating Leases figures came in at $6.8 million (Q1 2023), $7.0 million (Q4 2022), and $7.2 million (Q3 2022), per Business Quant data.